Amgen Reports Results From Two Studies Of Blincyto in Adolescent Leukemia Patients
September 24 2019 - 5:24PM
Dow Jones News
By Stephen Nakrosis
Amgen Inc. (AMGN) on Tuesday said results from a Phase 3 study
of Blincyto, a treatment for certain pediatric leukemia patients,
met their primary endpoint of event-free survival.
The company said the open-label, randomized, controlled global
multicenter Phase 3 trial "evaluated the efficacy, safety and
tolerability of Blincyto, or blinatumomab, compared to conventional
consolidation chemotherapy in pediatric patients with high-risk,
B-cell acute lymphoblastic leukemia at first relapse."
The company said enrollment in the study was halted early "due
to encouraging efficacy in the Blincyto arm."
A second study of Blincyto, conducted by the Children's Oncology
Group, was also halted early "based on a strong trend toward
improved disease-free survival and improved overall survival,
markedly lower toxicity, and better minimal residual disease
clearance," Amgen said.
"Considered together, the results of these studies are
remarkable. Children and adolescents who relapse with acute
lymphoblastic leukemia face a poor prognosis and there remains a
need for additional treatment options, particularly for those that
are identified as high-risk. These data have the potential to be
practice-changing and may provide a treatment approach to prevent
further relapse that is superior to chemotherapy," said David M.
Reese, M.D., executive vice president of Research and Development
at Amgen.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 24, 2019 17:09 ET (21:09 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024